<SEC-DOCUMENT>0001193125-20-273969.txt : 20201022
<SEC-HEADER>0001193125-20-273969.hdr.sgml : 20201022
<ACCEPTANCE-DATETIME>20201022060359
ACCESSION NUMBER:		0001193125-20-273969
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201021
FILED AS OF DATE:		20201022
DATE AS OF CHANGE:		20201022

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		201251562

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d28380d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated October 21, 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>IMMUTEP GRANTED EUROPEAN PATENT FOR IMP761</B></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: October 21, 2020 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d28380dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g28380g48d09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP GRANTED EUROPEAN PATENT FOR IMP761 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; </B><B>21</B><B></B><B>&nbsp;October 2020 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or
&#147;the Company&#148;), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 3344654) entitled <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;Anti-LAG-3</FONT></FONT> Antibodies&#148; by the European Patent Office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The claims of the patent are directed to
Immutep&#146;s <FONT STYLE="white-space:nowrap">pre-clinical</FONT> product candidate, IMP761, and also to the use of IMP761 in the treatment of <FONT STYLE="white-space:nowrap">T-cell</FONT> mediated inflammatory and autoimmune diseases. The expiry
date of the patent is 1&nbsp;September 2036. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep CEO, Marc Voigt stated</B>: &#147;IMP761 is the first agonist antibody that targets the immune
checkpoint <FONT STYLE="white-space:nowrap">LAG-3</FONT> and aims to treat the root cause of autoimmune diseases such as, for example, inflammatory bowel disease, rheumatoid arthritis and multiple sclerosis. It is very pleasing to see the grant of
this patent in the important European market which will underpin ongoing investment in this promising product candidate.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep CSO and CMO,
Dr.</B><B></B><B>&nbsp;Frederic Triebel also stated</B>: &#147;There continues to be a significant unmet medical need for patients with various autoimmune diseases and so it is highly encouraging to see the recent progress being made with IMP761
towards clinical development, both in terms of cell line development announced in April 2020 and now with securing intellectual property protection.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About IMP761 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP761 is a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunosuppressive agonist antibody to <FONT STYLE="white-space:nowrap">LAG-3.</FONT> As a targeted immunosuppressive antibody, IMP761 has the potential to
address the root cause of autoimmune diseases by specifically silencing the autoimmune memory T cells accumulating at the disease site which express <FONT STYLE="white-space:nowrap">LAG-3</FONT> as an exhaustion marker after being repeatedly
stimulated with dominant self-peptides. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2020, Immutep announced that its partner, Batavia Biosciences, had developed a pharmaceutical-grade,
stable CHO cell line that produces significantly high product yields of IMP761. The Company will now complete the preparations for the Good Manufacturing Practice (GMP) process compliance development phase, ahead of commencement of clinical testing
of the candidate in autoimmune disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in early 2019 Immutep reported encouraging preclinical results from its studies with IMP761. The in
vivo studies showed that IMP761 decreases inflammatory T cell infiltration induced by intra-dermal injection of an antigen. These findings were published in the <U>Journal of Immunology</U> in January 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology
company that is a leader in the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to
bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g28380g48d09.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product candidate is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;),
a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein <FONT STYLE="white-space:nowrap">(LAG-3Ig)</FONT> based on the <FONT STYLE="white-space:nowrap">LAG-3</FONT> immune control mechanism. This mechanism plays a vital role in the
regulation of the T cell immune response. Efti is currently in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT02614833); a Phase II clinical trial being conducted in
collaboration with Merck&nbsp;&amp; Co., Inc., Kenilworth, NJ, USA (known as &#147;MSD&#148; outside the United States and Canada) referred to as <FONT STYLE="white-space:nowrap">TACTI-002</FONT> to evaluate a combination of efti with KEYTRUDA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab) in several different solid tumours (clinicaltrials.gov identifier NCT03625323); a Phase I clinical trial being conducted in collaboration with Merck KGaA, Darmstadt, Germany and
Pfizer Inc. referred to as <FONT STYLE="white-space:nowrap">INSIGHT-004</FONT> to evaluate a combination of efti with avelumab (clinical trials.gov identifier NCT03252938); and a Phase I combination therapy trial in metastatic melanoma termed
TACTI-mel (clinicaltrials.gov identifier NCT02676869). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> products, including antibodies, for
immune response modulation in autoimmunity and cancer are being developed by Immutep&#146;s large pharmaceutical partners. Immutep is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the Company&#146;s website <U>www.immutep.com</U> or by contacting: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim McCarthy, LifeSci Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) 915.2564;&nbsp;<U>tim@lifesciadvisors.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the board of Immutep Limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level 12, 95 Pitt Street, Sydney NSW 2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g28380g48d09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g28380g48d09.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M/_DFI_Z\H_Y"@#%^%_74_P#MG_[-0!Z'0!XGJUX6\875U-%YX2Z/[LG[P4X
M_(4 =3_PLBZQC^Q?_(A_^)H Y_PS))_PFMI<1P-"DDS?( <*&!X_6@"Q\0_^
M1J;_ *XI_6@#UB'_ %$?^Z/Y4 >0^,8%TSQA*]L/+Y28!>,-U_F,T >OQMOB
M1L8R : '4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M' ZGUH IW6C:;>S>==6,$TN,;GC!.* +P 4  8 H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M]:.:0>TJ]V']KZW_ ,_=U^M'-(/:5>[#^U];_P"?NZ_6CFD'M*O=A_:^M_\
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M_=U^M'-(/:5>[#^U];_Y^[K]:.:0>TJ]V']KZW_S]W7ZT<T@]I5[L/[7UO\
MY^[K]:.:0>TJ]V']KZW_ ,_=U^M'-(/:5>[#^U];_P"?NZ_6CFD'M*O=A_:^
MM_\ /W=?K1S2#VE7NQG]L:Y_S]W?ZT<T@]I5[L]3KJ/6"@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
B"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
